Increasing evidence suggests that treatment with the low molecular weight heparin
enoxaparin during percutaneous coronary intervention (PCI) is safe and effective. We
evaluated the incidence and consequences of periprocedural macroscopic thrombus
formation on PCI equipment following antithrombin therapy with enoxaparin. Between April
2003 and December 2004, all patients undergoing cardiac catheterization following
antithrombin therapy with enoxaparin were evaluated. All patients had blood sampled at the …